The Vancouver Clinic

Vancouver, Washington 98686

2 studies enrolling now · 21 studies all time

What they study most

Chronic Rhinosinusitis With Nasal Polyposis, Crohn Disease, Crohn's Disease, Diabetes Mellitus, Type 2, Hypoparathyroidism, Lung Cancer, Meningococcal Vaccine, Meningococcal Vaccines, Moderately to Severely Active Crohns Disease, Primary Prevention of Sudden Cardiac Arrest, Rheumatoid Arthritis, Secondary Prevention of Sudden Cardiac Arrest

Studies at this site

• A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) — Running, not enrolling
• ABTECT - Maintenance — Running, not enrolling
• Screening for High Frequency Malignant Disease — Running, not enrolling
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Completed
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 — Completed
• S-ICD® System Post Approval Study — Completed
• A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
• An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis — Completed
• A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes — Completed
• Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY) — Completed
• Use of NPSP558 in the Treatment of Hypoparathyroidism — Completed
• A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE) — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease — Stopped early
• A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age — Completed
• A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17 — Completed
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling
• S-ICD® System IDE Clinical Study — Completed
• A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years — Completed